BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Amgen (AMGN)'s Xgeva Gains National Institute for Clinical Excellence (NICE) Recommendation for Bone Metastasis


8/17/2012 7:02:41 AM

NICE is continuing to recommend Amgen’s Xgeva for certain groups of cancer patients whose disease has spread to their bones. In final draft guidance the watchdog recommends Xgeva (denosumab) as a treatment for people with bone metastases from most solid cancer tumours. Specifically, it recommends the drug in patients with bone metastases from breast cancer and people with bone metastases from solid tumours (other than breast or prostate) that would otherwise be prescribed bisphosphonates. Xgeva works by preventing skeletal-related events from occurring from cancer - but not as an anti-cancer or pain relief treatment.

Read at InPharm.com
Read at Independent
Read at Press Assoc. (PA)
Read at News Release
Read at News Release


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->